课题基金 / 基金详情

Prevention of MGUS Progression to MM by Modulating the Bone Marrow Microenvironment

Prevention of MGUS Progression to MM by Modulating the Bone Marrow Microenvironment
通过调节骨髓微环境预防 MGUS 进展为 MM
批准号:
10745012
负责人:
FENGHUANG ZHAN
金额:
$29.04万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-01 至 2027-08-31

项目摘要

项目成果

FENGHUANG ZHAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY The long-term objective of this work is to determine the functional role of the bone marrow microenvironment in regulating the plasma cell growth of monoclonal gammopathy of undetermined significance (MGUS), using multiple MGUS mouse models to define reliable biomarkers. Our findings should form the basis for designing novel treatment approaches to prevent MGUS progression to multiple myeloma (MM). MGUS is a precancerous, but clonal condition with aberrant DNA changes in plasma cells (PC). The prevalence of MGUS increases with age. It is 3.2% at 50 years but rises to 9% for those older than 85, suggesting that risk factors associated with aging play an important role in MGUS development. MGUS may progress to smoldering multiple myeloma (SMM) and/or to MM, requiring therapy. Therefore, it is particularly important to identify and subsequently target the risk factors associated with MGUS progression. By studying MGUS mouse models and primary human samples from MGUS patients, we have demonstrated that bone marrow cellular senescence related to aging, iron metabolism, and increased DKK1 in MGUS plasma cells are linked to MGUS progression. We hypothesize that changes in the bone marrow microenvironment (ME) alter gene expression of MGUS plasma cells and induce both bone destruction and immunosuppression resulting in MGUS plasma cell proliferation and disease escape from effective immune surveillance. We propose three specific aims to prove this hypothesis: (1) determine the role of cellular senescence of ME in MGUS progression; (2) determine the role of DKK1 in promoting MGUS progression in adoptive transgenic mice; and (3) determine cellular and molecular mechanisms of MGUS progression. Our goal is to discover novel therapeutic approaches to prevent human MGUS progression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel NEK2 signaling pathways in myeloma progression
  • 批准号:
    10410522
  • 项目类别:
  • 资助金额:
    $34.07万
  • 财政年份:
    2020
  • 负责人:
    FENGHUANG ZHAN
  • 依托单位:
Novel NEK2 signaling pathways in myeloma progression - Bauer Diversity Supplement
  • 批准号:
    10598777
  • 项目类别:
  • 资助金额:
    $16.15万
  • 财政年份:
    2020
  • 负责人:
    FENGHUANG ZHAN
  • 依托单位:
Novel NEK2 signaling pathways in myeloma progression
  • 批准号:
    9883275
  • 项目类别:
  • 资助金额:
    $34.75万
  • 财政年份:
    2020
  • 负责人:
    FENGHUANG ZHAN
  • 依托单位:
Novel NEK2 signaling pathways in myeloma progression
  • 批准号:
    10626137
  • 项目类别:
  • 资助金额:
    $34.07万
  • 财政年份:
    2020
  • 负责人:
    FENGHUANG ZHAN
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: